Myriad Genetics, Inc. (MYGN)
MYGNNASDAQ-GSBiotechnology: In Vitro & In Vivo Diagnostic Substances
$5.57
-0.0900 (-1.59%) today
At the close, Nov 16, 4:00 PM ET. After hours $5.57 –
- Market cap
- $534.29m
- P/E
- –
- EPS, last 4 quarters
- $-0.6800
- Dividend yield
- –
- Day range
- $5.48 to $5.64
- 52-week range
- $2.74 to $8.09
- Average volume
- –
- Previous close
- $5.66
Analysts
6 coveringHold1 buy, 4 hold, 1 sell
Targets a year out average $5.69, +2.2% from here
Earnings
next estimate $-0.3300Next report
Dec 2025
+118.2%
Mar 2026
0.0%
Jun 2026
-312.5%
Sep 2026
+16.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $209.80m | $200.40m | $190.70m | $202.70m |
| Gross profit | $146.80m | $137.60m | $127.00m | $137.70m |
| Operating income | -$5.70m | -$30.70m | -$38.90m | -$39.90m |
| Net income | -$7.90m | -$34.10m | -$43.20m | -$43.90m |
Last four quarters: revenue $803.60m, margin -16.1%, free cash flow -$33.90m
News
8 latest- Myriad Genetics Consensus Price Target Increased by 21.17% to $5.55Fintel · Nov 9, 2026
- Myriad Genetics, Inc. Approves Retention Option Awards for Executive Officers on November 6, 2026Fintel · Nov 9, 2026
- Myriad Genetics Raises FY26 Revenue Outlook Midpoint; Agrees To Sell Prenatal Health Business RTTNews · Nov 6, 2026
- Myriad Genetics, Inc. Detects Unauthorized IT Network Access on November 2, 2026Fintel · Nov 5, 2026
- Myriad Genetics (MYGN) Q3 2026 Earnings Call TranscriptThe Motley Fool · Nov 5, 2026
- Myriad Genetics Reports Third Quarter 2026 Financial Results and Announces Agreement to Sell Prenatal Health BusinessFintel · Nov 4, 2026
- Myriad Genetics (MYGN) Reports Q3 Loss, Beats Revenue EstimatesZacks · Nov 4, 2026
- Myriad Genetics Q3 Earnings Call HighlightsMarketBeat · Nov 4, 2026
The company
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- myriad.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.